Literature DB >> 33682150

The impact of ABO blood groups on clinical outcomes and susceptibility to COVID-19: A retrospective study in an unselected population.

Sarah A Al-Youha1, Waleed Alduaij1,2, Ahmad Al-Serri3, Sulaiman M Almazeedi1, Mohannad Al-Haddad1, Mohammad H Jamal1,4, Andrew W Shih5,6, Salman K Al-Sabah1,4.   

Abstract

BACKGROUND: ABO blood groups have been linked to susceptibility to infection with certain microorganisms, including coronaviruses. We examined the relationship between blood group and clinical outcomes in individuals infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and compared their blood group distribution with the general population.
METHODS: At the inception of the pandemic, all individuals testing positive for SARS-CoV-2 in Kuwait were admitted to one designated coronavirus disease 2019 (COVID-19) hospital and enrolled in a prospective registry. Patients admitted from February 24 to May 27, 2020, were stratified according to blood group. As a control, blood groups of 3,730,027 anonymized individuals representing almost Kuwait's entire population were obtained from a national database.
RESULTS: Of 3305 SARS-CoV-2-positive patients, 37.1%, 25.5%, 28.9%, and 8.5% were groups O, A, B, and AB, respectively. Univariate analysis revealed no significant differences in severe clinical outcomes or death among the blood groups. However, multivariable analysis demonstrated that group A individuals had higher odds of developing pneumonia compared with non-group A (adjusted odds ratio 1.32, 95% confidence interval 1.02-1.72, p < .036). Compared with the general population, the COVID-19 cohort had a lower frequency of group O, equivalent frequency of A, and higher frequency of B and AB. No significant difference in the RhD group was found.
CONCLUSION: This study supports potential involvement of the ABO blood group system in predisposing to infection with SARS-CoV-2 in an unselected population. Examination of the mechanistic link between blood group and COVID-19 and its implications on controlling the current pandemic is warranted.
© 2021 AABB.

Entities:  

Keywords:  ABO blood groups; COVID-19; RhD antigen; SARS-CoV-2; coronavirus; pneumonia; severe COVID-19 disease

Mesh:

Substances:

Year:  2021        PMID: 33682150     DOI: 10.1111/trf.16365

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Association of ABO blood group with in-hospital adverse outcome and long term persistent symptoms of COVID-19 infection: A single-center longitudinal observational study.

Authors:  Ahmed Nafakhi; Ihsan S Rabeea; Rasha Al-Darraji; Hussein Nafakhi; Ahmed Mechi; Alhan Al-Khalidi; Mohammed Alareedh
Journal:  Health Sci Rep       Date:  2022-05-23

2.  Correlation between ABO Blood Group Phenotype and the Risk of COVID-19 Infection and Severity of Disease in a Saudi Arabian Cohort.

Authors:  Dunia Jawdat; Ali Hajeer; Salam Massadeh; Nora Aljawini; Malak S Abedalthagafi; Manal Alaamery
Journal:  J Epidemiol Glob Health       Date:  2022-01-03

Review 3.  Human Milk Oligosaccharides: Potential Applications in COVID-19.

Authors:  Somchai Chutipongtanate; Ardythe L Morrow; David S Newburg
Journal:  Biomedicines       Date:  2022-02-01

Review 4.  ABO blood groups and the risk of SARS-CoV-2 infection.

Authors:  Jörn Bullerdiek; Emil Reisinger; Birgit Rommel; Andreas Dotzauer
Journal:  Protoplasma       Date:  2022-04-01       Impact factor: 3.186

Review 5.  Fucosyltransferase 2: A Genetic Risk Factor for Intestinal Diseases.

Authors:  Mingyang Hu; Xiyun Zhang; Jinze Li; Luotong Chen; Xiaolin He; Tingting Sui
Journal:  Front Microbiol       Date:  2022-07-18       Impact factor: 6.064

6.  Blood-Type-A Is A COVID-19 Infection And Hospitalization Risk In A Turkish Cohort.

Authors:  Meryem Cetin; Sirin Cetin; Ayse Ulgen; Wentian Li
Journal:  Transfus Clin Biol       Date:  2022-10-12       Impact factor: 2.126

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.